135 related articles for article (PubMed ID: 30986908)
1. New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2.
Hamdy R; Elseginy SA; Ziedan NI; Jones AT; Westwell AD
Molecules; 2019 Apr; 24(7):. PubMed ID: 30986908
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Evaluation of New Bioactive Oxadiazole Derivatives as Anticancer Agents Targeting Bcl-2.
Hamdy R; Elseginy SA; Ziedan NI; El-Sadek M; Lashin E; Jones AT; Westwell AD
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256166
[TBL] [Abstract][Full Text] [Related]
3. New Bioactive Fused Triazolothiadiazoles as Bcl-2-Targeted Anticancer Agents.
Hamdy R; Jones AT; El-Sadek M; Hamoda AM; Shakartalla SB; Al Shareef ZM; Soliman SSM; Westwell AD
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830153
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 5-(1H-indol-3-yl)-N-aryl-1,3,4-oxadiazol-2-amines as Bcl-2 inhibitory anticancer agents.
Hamdy R; Ziedan NI; Ali S; Bordoni C; El-Sadek M; Lashin E; Brancale A; Jones AT; Westwell AD
Bioorg Med Chem Lett; 2017 Feb; 27(4):1037-1040. PubMed ID: 28087272
[TBL] [Abstract][Full Text] [Related]
5. Virtual screening, SAR, and discovery of 5-(indole-3-yl)-2-[(2-nitrophenyl)amino] [1,3,4]-oxadiazole as a novel Bcl-2 inhibitor.
Ziedan NI; Hamdy R; Cavaliere A; Kourti M; Prencipe F; Brancale A; Jones AT; Westwell AD
Chem Biol Drug Des; 2017 Jul; 90(1):147-155. PubMed ID: 28067996
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents.
Hamdy R; Ziedan N; Ali S; El-Sadek M; Lashin E; Brancale A; Jones AT; Westwell AD
Bioorg Med Chem Lett; 2013 Apr; 23(8):2391-4. PubMed ID: 23474389
[TBL] [Abstract][Full Text] [Related]
7. Therapeutics targeting Bcl-2 in hematological malignancies.
Ruefli-Brasse A; Reed JC
Biochem J; 2017 Oct; 474(21):3643-3657. PubMed ID: 29061914
[TBL] [Abstract][Full Text] [Related]
8. A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
Lavik AR; Zhong F; Chang MJ; Greenberg E; Choudhary Y; Smith MR; McColl KS; Pink J; Reu FJ; Matsuyama S; Distelhorst CW
Oncotarget; 2015 Sep; 6(29):27388-402. PubMed ID: 26317541
[TBL] [Abstract][Full Text] [Related]
9. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
[TBL] [Abstract][Full Text] [Related]
10. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
Roberts AW; Huang D
Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
[TBL] [Abstract][Full Text] [Related]
11. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.
Tam CS; Seymour JF; Roberts AW
Semin Oncol; 2016 Apr; 43(2):274-9. PubMed ID: 27040706
[TBL] [Abstract][Full Text] [Related]
12. A BH3 Mimetic for Killing Cancer Cells.
Green DR
Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
[TBL] [Abstract][Full Text] [Related]
13. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
14. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
[TBL] [Abstract][Full Text] [Related]
15. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening.
Enyedy IJ; Ling Y; Nacro K; Tomita Y; Wu X; Cao Y; Guo R; Li B; Zhu X; Huang Y; Long YQ; Roller PP; Yang D; Wang S
J Med Chem; 2001 Dec; 44(25):4313-24. PubMed ID: 11728179
[TBL] [Abstract][Full Text] [Related]
16. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.
Billard C
Leukemia; 2012 Sep; 26(9):2032-8. PubMed ID: 22453662
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
18. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
19. Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells.
Pidugu VR; Yarla NS; Bishayee A; Kalle AM; Satya AK
Apoptosis; 2017 Nov; 22(11):1394-1403. PubMed ID: 28840369
[TBL] [Abstract][Full Text] [Related]
20. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
